CIS Insulin Market

The global CIS insulin market size is estimated to register a considerable CAGR during the forecast period, 2021-2028. The growth of the market is attributed to the increasing prevalence of diabetes across the globe due to changing lifestyle of people.

Get Free Sample Report

A peptide hormone produced by the pancreas is one of the key hormones for the human body. It helps the regulation of glucose into the blood cells and regulates the metabolism of fats and carbohydrates. When insulin is not produced in a sufficient amount in the body, it leads to sugar accumulation in the blood that results in diabetes. Diabetes is treated by providing insulin externally to the patient. As per the estimation by the International Diabetes Federation, the number of diabetic patients is expected to grow from 366 million in 2011 to 552 million in 2030. The report also stated that in 2013 approximately 382 million individuals were diagnosed with diabetes. Hence the rapid increase in the number of diabetic patients is expected to drive the market expansion.

There are about 100 million individuals around the world who need insulin. This also includes the number of patients who are suffering from type I and type II diabetes. Insulin has been used for the treatment of diabetes for over 90 years; however, still many people in need across several parts of regions are unable to afford and access it. In order to prevent complications, type I diabetic patients are treated with insulin to maintain the sugar level in their blood along with taking care of their lifestyle and diet.

Market Trends, Drivers, Restraints, and Opportunities

• Wide consumption of the fast-food products and high intake of sugar-based food products are anticipated to fuel the market growth during the forecast period.
• Commercialization of insulin products at a very large scale leads to deeper penetration among patients, which is anticipated to drive the market expansion in the coming years.
• Launch of new products in the market coupled with the establishment of regulations that favors the CIS insulin manufacturers present a major driver to boost the market growth.
• Rising geriatric population base along with the growing development of  low price of insulin products is estimated to drive the market growth during the forecast period.
• High cost of insulin and difficulty in its accessibility are key restraining factors anticipated to restrain the market growth.
• Ongoing research & development activities by insulin developers coupled with agreements made between the local governments are projected to present key lucrative opportunities for market growth.

Scope of the Report

The report on the global CIS insulin market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.

Market Segment Insights

Long-acting analog segment is anticipated to dominate the market

On the basis of products, the global CIS insulin market is divided into intermediate insulin, rapid acting analog, short acting insulin, premixed analog, premixed insulin, and long-acting analog. The long-acting analog segment held a large revenue share of the market in 2019 and is anticipated to dominate the market during the forecast period owing to its high cost.

Get Free Sample Report

Analogs segment is expected to account for a major revenue share

Based on sources, the market is bifurcated into analogs and human recombinant insulin. Several insulin products are derived from various sources. The analogs segment is expected to account for a major revenue share of the market during the projected period owing to the penetration of various new products deep in the market.

Type I diabetes segment is estimated to exhibit high revenue growth

On the basis of applications, the global CIS insulin market is bifurcated into type I diabetes and type II diabetes. The type I diabetes segment is estimated to exhibit high revenue growth of the market in the coming years owing to the increasing use of insulin for the treatment of type I diabetes along with the introduction of various new products in the market.

Europe is expected to dominate the market

In terms of regions, the global CIS insulin market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. Europe is expected to dominate the market during the forecast period in terms of revenue attributed to subsidies provided by different governments in the region so that the medicines are easily accessible and affordable to common people. The further acceleration of the regional market growth is attributed to the well-establishment of healthcare service systems provided by the governments and wide funding for the development of biosimilar products.

Get Free Sample Report

Segments

The global CIS insulin market has been segmented on the basis of

Products

• Intermediate Insulin
• Rapid Acting Analog
• Short Acting Insulin
• Premixed Analog
• Premixed Insulin
• Long-acting Analog

Sources

• Analogs
• Human Recombinant Insulin

Applications

• Type I Diabetes
• Type II Diabetes

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Boehringer Ingelheim
• Novo Nordisk
• Sanofi Aventis
• Takeda Pharmaceuticals
• Nanjing Xinbai Pharmaceutical Co. Ltd.
• Merck & Co. Inc.
• Oramed Pharmaceuticals
• Eli Lilly and Co.
• Biocon

Competitive Landscape

Key players competing in the global CIS insulin market are Boehringer Ingelheim; Novo Nordisk; Sanofi Aventis; Takeda Pharmaceuticals; Nanjing Xinbai Pharmaceutical Co. Ltd.; Merck & Co. Inc.; Oramed Pharmaceuticals; Eli Lilly and Co.; and Biocon. Many of these players have adopted business strategies such as development of novel drugs, launch of new products, advancement of technologies, partnerships, mergers, and production capacity expansion in order to increase their expansion, their consumer base, and market position globally.